Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Cassava Sciences Approves Executive Cash Bonuses for 2025

Tipranks - Tipranks - Thu Dec 18, 2025

Claim 50% Off TipRanks Premium and Invest with Confidence

Cassava Sciences ( (SAVA) ) has issued an announcement.

On December 12, 2025, Cassava Sciences‘ Board of Directors approved cash bonus awards for its executives in recognition of their significant contributions in 2025. The company achieved progress on performance measures, including exploring the use of its drug simufilam in Tuberous Sclerosis Complex-related epilepsy, building a specialized team, and managing budgets effectively to support these objectives.

The most recent analyst rating on (SAVA) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Cassava Sciences stock, see the SAVA Stock Forecast page.

Spark’s Take on SAVA Stock

According to Spark, TipRanks’ AI Analyst, SAVA is a Neutral.

Cassava Sciences faces significant financial challenges with no revenue and ongoing operational losses, reflected in the low financial performance score. Technical indicators show bearish trends, and the negative P/E ratio emphasizes valuation concerns. However, the strategic license agreement with Yale University could offer future growth potential, though it currently holds minimal weight due to its speculative nature.

To see Spark’s full report on SAVA stock, click here.

More about Cassava Sciences

Cassava Sciences operates in the biotechnology industry, with a focus on innovative treatments for neurological disorders. The company aims to develop transformative advancements in healthcare, particularly through its work with simufilam, a potential therapeutic for conditions like Alzheimer’s disease and epilepsy.

Average Trading Volume: 2,804,434

Technical Sentiment Signal: Sell

Current Market Cap: $141.5M

See more insights into SAVA stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Trending Articles

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).